Vitiligo adverse events and associated medications as reported in the US Food and Drug Administration’s Adverse Event Reporting System from 2016 to 2021

Vitiligo induced by dupilumab treatment: A case series

“…Immune checkpoint inhibitors, BRAF inhibitors and biologics such as TNFɑ, IL17 and IL12/23 inhibitors for psoriasis, have been known to worsen vitiligo. [2][3][4][5] Dupilumab, a human interleukin-4 receptor alpha antagonist, inhibits interleukins-4 and 13, which promote type 2 cytokine inflammation in atopic dermatitis (AD). Adverse events such as injection site reactions, conjunctivitis, blepharitis, herpes virus infections, keratitis, eye pruritus, dry eye and alopecia areata have commonly been reported, [6][7][8] but vitiligo has only been described in one patient with atopic dermatitis treated with dupilumab to date.…”